Evidence map›Paper›PMID 39758230›Full record

ArticleCancer diagnosis & prognosis

Tumor β-Catenin Expression Associated With Poor Prognosis to Anti-PD-1 Antibody Monotherapy in Non-small Cell Lung Cancer.

Satoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, Masayuki Watanabe, Naoyuki Okabe, Yuki Matsumura, Kazuyuki Hamada, Hiroyuki Suzuki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Satoshi MutoDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Yuki OzakiDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Hikaru YamaguchiDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Masayuki WatanabeDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Naoyuki OkabeDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Yuki MatsumuraDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Kazuyuki HamadaDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Hiroyuki SuzukiDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Tumor intrinsic β-catenin signaling has been reported to influence the tumor immune microenvironment and may be a resistance mechanism to immune checkpoint inhibitors in various cancers. Patients and Methods: We studied the association between tumor β-catenin expression and survival in 50 patients with non-small cell lung cancer (NSCLC) treated with anti-programmed death-1 antibody monotherapy. Tumor β-catenin expression was evaluated by immunohistochemistry. Results: Patients with positive tumor β-catenin expression (20% of all patients) had worse progression-free survival and overall survival compared with those with negative tumor β-catenin expression. Patients with positive tumor β-catenin expression had reduced CD8 Conclusion: NSCLC patients with positive tumor β-catenin expression that were treated with anti-programmed death-1 antibody monotherapy had poor prognosis.

Indexed as

beta-cateninCancer immunotherapynon-small cell lung cancertumor immune evasiontumor-infiltrating lymphocytes

Identifiers

PMID39758230
PMCPMC11696345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.